At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 26 enrolled
Drug / intervention
TLPLDC Vaccinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease.
In Brief
A Phase 2 clinical trial evaluating TLPLDC Vaccine for Metastatic Melanoma. Completed, enrolled 26 participants across 7 sites.
Detailed Summary
Assess the safety and tumor response of utilizing an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine given in combination with standard of care (SoC) checkpoint inhibitors (CPI) in patients with stage IV melanoma with measurable disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Melanoma
CountriesUnited States
CollaboratorsLumaBridge
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartFeb 2016
First PostedFeb 2016
Primary CompletionOct 2019
Study CompletionNov 2019
TodayJul 2026
First PostedFeb 10, 2016
Enrollment StartFeb 1, 2016
Primary CompletionOct 30, 2019
Study CompletionNov 13, 2019
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 10.4 years ago
Interventions
TLPLDC Vaccinedrug
Tumor Lysate, Particle Loaded, Dendritic Cell Vaccine